Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$38.8541
-0.11(-0.3%)
as of November 6, 2025
Try our APIs with
free plan!
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
38.8541
Open
38.7482
High
39.3922
Low
38.3882
52 wk Range
17.82-42.05
Market Cap
2 967 M
P/E Ratio
86.9778
Shares Outstanding
45 161 K
Revenue
598 M
EPS
0.23
Beta
0.025
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 598 M
- EBITDA: 39 641 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.3139
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
High Growth Tech Opportunities in the US Market
In the current climate, major U.S. stock indexes have experienced significant declines, with tech-heavy indices like the Nasdaq Composite dropping nearly 2% amid broader market volatility and concerns...
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve
Even though Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) posted strong earnings, investors appeared to be underwhelmed. Our analysis says that investors should be optimistic, as the stron...
New Strong Sell Stocks for Oct. 30th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Equinox Gold EQX engages in the acquisition, exploration and development of mineral deposits. The Zacks Consensus Estimate f...
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win
Kiniksa Pharmaceuticals (KNSA) just delivered its third quarter earnings, highlighting an impressive jump in ARCALYST revenue and a shift to positive net income. The company also updated its guidance,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
